Clinical Trials
16 trialsNCT06096779 2026-05-04
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT05586516 2026-03-30
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Completed
NCT05064553 2025-10-15
ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk
Exact Sciences Corporation
Active not recruiting
NCT05201404 2025-04-29
LIVERATION
Can-Fite BioPharma
Phase 3 Recruiting
NCT05683548 2025-02-17
RCAP
Replicor Inc.
No longer available
NCT05635266 2024-05-07
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
Recruiting
NCT05716919 2023-10-23
Multiple Ascending Dose Study of CG200745 'Ivaltinostat' Oral Capsule
Machaon Biotherapeutics, Inc.
Phase 1 Unknown
NCT00375011 2022-12-20
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
Meridian Bioscience, Inc.
Terminated
NCT02224456 2022-02-14
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
GlaxoSmithKline
Phase 4 Completed
NCT01981850 2022-01-05
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Hoffmann-La Roche
Phase 2 Completed
NCT04264754 2021-05-06
Characterization of Methylation Patterns in Hepatocellular Carcinoma
Nucleix Ltd.
Terminated
NCT02232490 2019-02-26
Hepko-V5
Immunitor LLC
Phase 3 Unknown
NCT01562821 2017-01-13
Safety and Efficacy of Activated Recombinant Human Factor VII in Cirrhotic Patients Undergoing Partial Hepatectomy
Novo Nordisk A/S
Phase 2 Completed
NCT00802555 2012-07-12
Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00502086 2011-02-11
Efficacy and Safety of Viusid in Patients With Hepatic Cirrhosis Secondary to Hepatitis C Virus Infection.
Catalysis SL
Phase 3 Completed
NCT00237523 2007-06-18
Study for Treatment of Moderate or Severe, Periodic, "Cyclic", Breast Pain
Symbollon Pharmaceuticals
Phase 3 Unknown